About Lunai Bioworks Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://renovarobio.com/
Frequently Asked Questions
What is the 52-week range for LNAI?
The 52-week high is $13.28 and the 52-week low is $1.21.
What is the P/E ratio for LNAI?
The P/E ratio data is currently unavailable.
What is the dividend yield for LNAI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -67.00%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest LNAI News
Stock Market: Will S&P 500 Open Up or Down Today?
S&P 500 to open higher? Polymarket odds reach 70% as Wall Street digests September jobs, 24-year high Treasury yields, and Iran sanctions.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV) shares moved
Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M
The Company anticipates reporting a net loss for the fiscal year ended June 30, 2026 of approximately $3.2 million, compared to a net loss of approximately $178.0 million for the fiscal year ended June 30, 2025. The
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform. The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular bio
Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform
The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
Lunai Bioworks, Inc. (Nasdaq: LNAI) ("Lunai" or the "Company") today shared results from a technical case study conducted by its BioSymetrics subsidiary, supporting the development of structure-based screening tools for chemical outputs generated by large language models and other artificial intelligence systems. The study evaluates predicting acetylcholinesterase ("AChE") inhibition directly from molecular structure as a model-agnostic component of the Company's broader chemical-safety and bios